The clinical use of ctDNA as a biomarker in TNBC

Michail Ignatiadis, MD, PhD, Institut Jules Bordet, Brussels, Belgium, discusses the use of circulating tumor DNA (ctDNA) in triple-negative breast cancer (TNBC). Whilst a promising biomarker, ctDNA has not yet validated its clinical utility, and studies such as TRACK-TN (NCT03145961) suggest newer, more sensitive detection technology is needed as patients already had metastatic disease upon ctNDA detection. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.